Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study of ADG106 in combination with other therapies in advanced solid tumors and hematological malignancies

Next Previous
Trial Profile

Clinical study of ADG106 in combination with other therapies in advanced solid tumors and hematological malignancies

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 24 May 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ADG 106 (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions

Most Recent Events

  • 24 May 2021 New trial record
  • 19 May 2021 According to an Adagene media release, preparations are underway to initiate this study.
  • 31 Mar 2021 According to an Adagene media release, Phase 1b read-out from Australia trial in combination therapy in 2H21

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top